Four Ways To Draw DDMAC's Ire: In Print, On A Dosing Card, In A Script, And In Person
This article was originally published in The Pink Sheet Daily
Executive Summary
In a series of letters, FDA cites Lilly, Cephalon, Bayer and Amylin for promotional violations.
You may also be interested in...
ParaGard TV Spot Misrepresents Contraceptive’s Risks, US FDA Says
‘Untitled’ letter is FDA's third in the past eighteen months to target promotions for women’s health products. In the case of advertisement for CooperSurgical's copper-containing intrauterine device, which is regulated as a drug, the agency took issue with distracting visuals and reliance on superimposed text.
US FDA Advertising Citations Remain Rare In 2018
With only seven letters last year, Office of Prescription Drug Promotion appears to be continuing its enforcement retrenchment as agency reconsiders its approach to Rx communications.
FDA Cites Imaging Drug Web Sites, Draws "Respectful" Disagreement
Bracco Diagnostics took down a promotional Web site in response to an untitled letter from DDMAC but disagrees that it hyped a study. GE Healthcare's Visipaque is cited in a separate letter.